BACKGROUND AND OBJECTIVE: Oral mucositis, a painful condition with potentially life-threatening sequelae, often develops in association with allogeneic bone marrow transplantation. This condition has an adverse impact on the oral-health-related quality of life of patients undergoing marrow transplantation therapy. The purpose of this study was to create and validate a Patient-Reported Oral Mucositis Symptom (PROMS) scale. This scale allows evaluation of symptoms of oral mucositis that threaten quality of life. MATERIALS AND METHODS: The PROMS scale was compared with previously validated tools measuring quality of life (Functional Assessment of Cancer Therapy--Bone Marrow Transplant), symptoms of depression (Center for Epidemiologic Studies Depression Scale), psychological well-being (Affect Balance Scale) and stressful life events, as well as an objective, clinician-rated assessment of oral mucositis (Visual Analogue Scale--Oral Mucositis Assessment Scale). Thirty-four patients who were to undergo allogeneic bone marrow transplantation at Princess Margaret Hospital in Toronto, Ontario, were enrolled in this validation study. RESULTS: The PROMS scale had high internal reliability, as well as good convergent and discriminant validity relative to subjective measures of well-being. Longitudinal assessments showed that changes in PROMS scores were strongly correlated with changes in clinical assessment of oral mucositis over the first 2 weeks after transplantation, when the onset of oral mucositis typically occurs and the lesions are most severe. CONCLUSIONS: Oral mucositis in patients who have undergone bone marrow transplantation can be quantified reliably with the easily administered PROMS scale. The PROMSscale provides a valid measure of the impact of oral mucositis on the oral-health-related quality of life of patients affected by this malady.
BACKGROUND AND OBJECTIVE:Oral mucositis, a painful condition with potentially life-threatening sequelae, often develops in association with allogeneic bone marrow transplantation. This condition has an adverse impact on the oral-health-related quality of life of patients undergoing marrow transplantation therapy. The purpose of this study was to create and validate a Patient-Reported Oral Mucositis Symptom (PROMS) scale. This scale allows evaluation of symptoms of oral mucositis that threaten quality of life. MATERIALS AND METHODS: The PROMS scale was compared with previously validated tools measuring quality of life (Functional Assessment of Cancer Therapy--Bone Marrow Transplant), symptoms of depression (Center for Epidemiologic Studies Depression Scale), psychological well-being (Affect Balance Scale) and stressful life events, as well as an objective, clinician-rated assessment of oral mucositis (Visual Analogue Scale--Oral Mucositis Assessment Scale). Thirty-four patients who were to undergo allogeneic bone marrow transplantation at Princess Margaret Hospital in Toronto, Ontario, were enrolled in this validation study. RESULTS: The PROMS scale had high internal reliability, as well as good convergent and discriminant validity relative to subjective measures of well-being. Longitudinal assessments showed that changes in PROMS scores were strongly correlated with changes in clinical assessment of oral mucositis over the first 2 weeks after transplantation, when the onset of oral mucositis typically occurs and the lesions are most severe. CONCLUSIONS:Oral mucositis in patients who have undergone bone marrow transplantation can be quantified reliably with the easily administered PROMS scale. The PROMSscale provides a valid measure of the impact of oral mucositis on the oral-health-related quality of life of patients affected by this malady.
Authors: Karis Kin Fong Cheng; Vincent Lee; Chak Ho Li; Hui Leung Yuen; Joel B Epstein Journal: Support Care Cancer Date: 2011-12-14 Impact factor: 3.603
Authors: Jacolien Bos-den Braber; Carin M J Potting; Ewald M Bronkhorst; Marie-Charlotte D N J M Huysmans; Nicole M A Blijlevens Journal: Support Care Cancer Date: 2014-06-08 Impact factor: 3.603
Authors: Midori Nakagaki; Nicole C Gavin; Alexandra Clavarino; Glen A Kennedy; Karen Whitfield Journal: Support Care Cancer Date: 2021-11-25 Impact factor: 3.603
Authors: Ajay Prashad Gautam; Donald J Fernandes; Mamidipudi S Vidyasagar; Arun G Maiya; Shantling Nigudgi Journal: Support Care Cancer Date: 2012-12-08 Impact factor: 3.603
Authors: Deborah Tomlinson; Faith Gibson; Nathaniel Treister; Christina Baggott; Peter Judd; Eleanor Hendershot; Anne-Marie Maloney; John Doyle; Brian Feldman; Lillian Sung Journal: Support Care Cancer Date: 2008-11-04 Impact factor: 3.603
Authors: Gary Deng; Sergio Giralt; David J Chung; Heather Landau; Jonathan Siman; Qing S Li; Kaitlyn Lapen; Jun J Mao Journal: Pain Med Date: 2020-03-01 Impact factor: 3.750
Authors: Karis Kin-Fong Cheng; S F Leung; Raymond H S Liang; Josepha W M Tai; Rebecca M W Yeung; David R Thompson Journal: Support Care Cancer Date: 2009-11-15 Impact factor: 3.603